-
Chiesi Wins FDA Approval for First Drug to Treat Ultra-Rare Enzyme Deficiency
Chiesi Wins FDA Approval for First Drug to Treat Ultra-Rare Enzyme Deficiency Chiesi drug Lamzede is an engineered version of an enzyme that’s lacking in patients with the rare disease alpha-mannosidosis. FDA approval of the Chiesi drug comes about five years after European regulators authorized the product. Information Courtesy By: Frank Vinluan, #HealthcareNews #Healthcare |…
-
The Adderall Shortage
The Adderall Shortage The increased demand for stimulant medications such as Adderall for ADHD is not the result of abuse or misdiagnosis but is caused by a previously unmet need for treatment of ADHD, which telepsychiatry finally satisfied. Information Courtesy By: David Brody, #HealthcareNews #Healthcare | Feeds The increased demand for stimulant medications such as…
-
Moderna Flu Vax Prompts Response to More Common Strains, But Misses in Influenza B
Moderna Flu Vax Prompts Response to More Common Strains, But Misses in Influenza B Moderna’s mRNA vaccine for influenza has early data from a pivotal study showing it met trial goals assessing immune response against the more common strains of the virus, but missed against two less common types. A separate and ongoing Phase 3…
-
Cell Therapy Biotech Talaris Ends Two Kidney Transplant Trials, Restructures
Cell Therapy Biotech Talaris Ends Two Kidney Transplant Trials, Restructures While Talaris Therapeutics is ending two clinical tests of its cell therapy in kidney transplant patients, a third study in the autoimmune condition scleroderma is continuing. Meanwhile, the biotech’s restructuring plan is pursuing “strategic alternatives” that could include a merger or sale. Information Courtesy By:…
-
MD Anderson’s Tech Puts Replay on Fast Path to Clinic With TCR NK Cell Therapies
MD Anderson’s Tech Puts Replay on Fast Path to Clinic With TCR NK Cell Therapies Syena, the latest company formed by startup creator Replay, is developing cancer treatments based on a type of immune cell called a natural killer cell. This NK cell therapy technology, licensed from The University of Texas MD Anderson Cancer Center,…
-
Biotech Funding Roundup: 7 Startups Raise More Than $200M in Capital
Biotech Funding Roundup: 7 Startups Raise More Than $200M in Capital Tilt Biotherapeutics, Evonetix, and Garuda Therapeutics are among the biotech startups that raised money in the past week. Information Courtesy By: Frank Vinluan, #HealthcareNews #Healthcare | Feeds Tilt Biotherapeutics, Evonetix, and Garuda Therapeutics are among the biotech startups that raised money in the past…
-
Weight Loss in a Pill Device Firm Allurion Heads to NYSE via SPAC Merger
Weight Loss in a Pill Device Firm Allurion Heads to NYSE via SPAC Merger Allurion Technologies has developed a gastric balloon that does not require surgery. The merger deal taking Allurion public comes as the company continues global commercialization of its technology. Information Courtesy By: Frank Vinluan, #HealthcareNews #Healthcare | Feeds Allurion Technologies has developed…
Got any book recommendations?